A Phase 2, Placebo-Controlled, Randomized, Double-Blinded, Multicenter, Study To Evaluate The Bleeding Profile Of 2.5 Mg And 5.0 Mg Bid Apixaban In Combination With Standard Therapy In Patients With Recent (less than or equal to 7 Days) Acute Coronary Syndrome (ACS).

Trial Profile

A Phase 2, Placebo-Controlled, Randomized, Double-Blinded, Multicenter, Study To Evaluate The Bleeding Profile Of 2.5 Mg And 5.0 Mg Bid Apixaban In Combination With Standard Therapy In Patients With Recent (less than or equal to 7 Days) Acute Coronary Syndrome (ACS).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2013

At a glance

  • Drugs Apixaban (Primary)
  • Indications Acute coronary syndromes; Thrombosis
  • Focus Adverse reactions
  • Acronyms APPRAISE-J
  • Most Recent Events

    • 22 Aug 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Jul 2010 Planned end date changed from 1 Oct 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top